# Intellicheck, Inc.: financial statements, quarterly

IDN · Nasdaq · CIK 1040896 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/idn.md) · [Financials](/companies/idn/financials.md) · [Filings](/companies/idn/filings.md) · [Insiders](/companies/idn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/idn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [4,760](/filings/0001628280-24-047890.md) | [5,176 d](/filings/0001628280-25-015555.md) | [4,680](/filings/0001628280-25-025086.md) | [4,672](/filings/0001040896-25-000017.md) | [4,709](/filings/0001040896-25-000032.md) | [5,937 d](/filings/0001040896-26-000009.md) | [4,894](/filings/0001040896-26-000020.md) | [5,123](/filings/0001040896-26-000035.md) | [6,014](/filings/0001040896-25-000032.md) | [6,635 d](/filings/0001040896-26-000009.md) | [5,524](/filings/0001040896-26-000020.md) | [5,941](/filings/0001040896-26-000035.md) |
| Cost of revenue | $k | [428](/filings/0001628280-24-047890.md) | [263 d](/filings/0001628280-25-015555.md) | [435](/filings/0001628280-25-025086.md) | [444](/filings/0001040896-25-000017.md) | [424](/filings/0001040896-25-000032.md) | [528 d](/filings/0001040896-26-000009.md) | [502](/filings/0001040896-26-000020.md) | [523](/filings/0001040896-26-000035.md) | [571](/filings/0001040896-25-000032.md) | [570 d](/filings/0001040896-26-000009.md) | [499](/filings/0001040896-26-000020.md) | [517](/filings/0001040896-26-000035.md) |
| Gross profit | $k | [4,332](/filings/0001628280-24-047890.md) | [4,913 d](/filings/0001628280-25-015555.md) | [4,245](/filings/0001628280-25-025086.md) | [4,228](/filings/0001040896-25-000017.md) | [4,285](/filings/0001040896-25-000032.md) | [5,409 d](/filings/0001040896-26-000009.md) | [4,392](/filings/0001040896-26-000020.md) | [4,600](/filings/0001040896-26-000035.md) | [5,443](/filings/0001040896-25-000032.md) | [6,065 d](/filings/0001040896-26-000009.md) | [5,025](/filings/0001040896-26-000020.md) | [5,424](/filings/0001040896-26-000035.md) |
| Research and development | $k | [1,550](/filings/0001628280-24-047890.md) | [546 d](/filings/0001628280-25-015555.md) | [819](/filings/0001628280-25-025086.md) | [835](/filings/0001040896-25-000017.md) | [1,177](/filings/0001040896-25-000032.md) | [1,028 d](/filings/0001040896-26-000009.md) | [1,287](/filings/0001040896-26-000020.md) | [1,363](/filings/0001040896-26-000035.md) | [1,391](/filings/0001040896-25-000032.md) | [1,273 d](/filings/0001040896-26-000009.md) | [1,241](/filings/0001040896-26-000020.md) | [1,370](/filings/0001040896-26-000035.md) |
| Selling, general and administrative | $k | [3,677](/filings/0001628280-24-047890.md) | [3,518 d](/filings/0001628280-25-015555.md) | [3,949](/filings/0001628280-25-025086.md) | [3,608](/filings/0001040896-25-000017.md) | [4,018](/filings/0001040896-25-000032.md) | [3,915 d](/filings/0001040896-26-000009.md) | [3,453](/filings/0001040896-26-000020.md) | [3,535](/filings/0001040896-26-000035.md) | [3,814](/filings/0001040896-25-000032.md) | [3,298 d](/filings/0001040896-26-000009.md) | [3,242](/filings/0001040896-26-000020.md) | [3,481](/filings/0001040896-26-000035.md) |
| Operating income | $k | [(895)](/filings/0001628280-24-047890.md) | [849 d](/filings/0001628280-25-015555.md) | [(523)](/filings/0001628280-25-025086.md) | [(215)](/filings/0001040896-25-000017.md) | [(910)](/filings/0001040896-25-000032.md) | [466 d](/filings/0001040896-26-000009.md) | [(348)](/filings/0001040896-26-000020.md) | [(298)](/filings/0001040896-26-000035.md) | [238](/filings/0001040896-25-000032.md) | [1,494 d](/filings/0001040896-26-000009.md) | [542](/filings/0001040896-26-000020.md) | [573](/filings/0001040896-26-000035.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [8.0](/filings/0001628280-24-047890.md) | [(82.0) d](/filings/0001628280-25-015555.md) | [2.0](/filings/0001628280-25-025086.md) | [0.0](/filings/0001040896-25-000017.md) | [0.0](/filings/0001040896-25-000032.md) | [31.0 d](/filings/0001040896-26-000009.md) | [0.0](/filings/0001040896-26-000020.md) | [0.0](/filings/0001040896-26-000035.md) | [0.0](/filings/0001040896-25-000032.md) | [58.0 d](/filings/0001040896-26-000009.md) | [0.0](/filings/0001040896-26-000020.md) | [0.0](/filings/0001040896-26-000035.md) |
| Net income | $k | [(724)](/filings/0001628280-24-047890.md) | [984 d](/filings/0001628280-25-015555.md) | [(442)](/filings/0001628280-25-025086.md) | [(127)](/filings/0001040896-25-000017.md) | [(837)](/filings/0001040896-25-000032.md) | [488 d](/filings/0001040896-26-000009.md) | [(318)](/filings/0001040896-26-000020.md) | [(251)](/filings/0001040896-26-000035.md) | [290](/filings/0001040896-25-000032.md) | [1,552 d](/filings/0001040896-26-000009.md) | [636](/filings/0001040896-26-000020.md) | [663](/filings/0001040896-26-000035.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0001628280-24-047890.md) | not reported | [(0.02)](/filings/0001628280-25-025086.md) | [(0.01)](/filings/0001040896-25-000017.md) | [(0.04)](/filings/0001040896-25-000032.md) | not reported | [(0.02)](/filings/0001040896-26-000020.md) | [(0.01)](/filings/0001040896-26-000035.md) | [0.01](/filings/0001040896-25-000032.md) | not reported | [0.03](/filings/0001040896-26-000020.md) | [0.03](/filings/0001040896-26-000035.md) |
| Basic EPS | $ per share | [(0.04)](/filings/0001628280-24-047890.md) | not reported | [(0.02)](/filings/0001628280-25-025086.md) | [(0.01)](/filings/0001040896-25-000017.md) | [(0.04)](/filings/0001040896-25-000032.md) | not reported | [(0.02)](/filings/0001040896-26-000020.md) | [(0.01)](/filings/0001040896-26-000035.md) | [0.01](/filings/0001040896-25-000032.md) | not reported | [0.03](/filings/0001040896-26-000020.md) | [0.03](/filings/0001040896-26-000035.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.0](/filings/0001628280-23-038914.md) | [4.0](/filings/0001628280-25-015555.md) | [9.2](/filings/0001628280-24-023185.md) | [7.3](/filings/0001628280-24-037186.md) | [5.7](/filings/0001628280-24-047890.md) | [4.7](/filings/0001040896-26-000009.md) | [5.1](/filings/0001628280-25-025086.md) | [8.6](/filings/0001040896-25-000017.md) | [7.2](/filings/0001040896-25-000032.md) | [9.7](/filings/0001040896-26-000035.md) | [10.1](/filings/0001040896-26-000020.md) | [11.8](/filings/0001040896-26-000035.md) |
| Current assets | $m | [13.4](/filings/0001628280-23-038914.md) | [14.4](/filings/0001628280-25-015555.md) | [12.6](/filings/0001628280-24-023185.md) | [11.2](/filings/0001628280-24-037186.md) | [9.6](/filings/0001628280-24-047890.md) | [9.9](/filings/0001040896-26-000009.md) | [13.5](/filings/0001628280-25-025086.md) | [12.1](/filings/0001040896-25-000017.md) | [14.5](/filings/0001040896-25-000032.md) | [13.9](/filings/0001040896-26-000035.md) | [16.7](/filings/0001040896-26-000020.md) | [15.3](/filings/0001040896-26-000035.md) |
| Total assets | $m | [22.4](/filings/0001628280-23-038914.md) | [23.8](/filings/0001628280-25-015555.md) | [22.6](/filings/0001628280-24-023185.md) | [21.9](/filings/0001628280-24-037186.md) | [20.7](/filings/0001628280-24-047890.md) | [20.9](/filings/0001040896-26-000009.md) | [24.6](/filings/0001628280-25-025086.md) | [23.1](/filings/0001040896-25-000017.md) | [25.3](/filings/0001040896-25-000032.md) | [24.5](/filings/0001040896-26-000035.md) | [27.1](/filings/0001040896-26-000020.md) | [25.6](/filings/0001040896-26-000035.md) |
| Current liabilities | $m | [5.3](/filings/0001628280-23-038914.md) | [6.5](/filings/0001628280-25-015555.md) | [5.4](/filings/0001628280-24-023185.md) | [4.6](/filings/0001628280-24-037186.md) | [3.9](/filings/0001628280-24-047890.md) | [3.2](/filings/0001040896-26-000009.md) | [7.0](/filings/0001628280-25-025086.md) | [5.1](/filings/0001040896-25-000017.md) | [6.4](/filings/0001040896-25-000032.md) | [3.8](/filings/0001040896-26-000035.md) | [5.6](/filings/0001040896-26-000020.md) | [3.1](/filings/0001040896-26-000035.md) |
| Total liabilities | $m | [5.3](/filings/0001628280-23-038914.md) | [6.5](/filings/0001628280-25-015555.md) | [5.4](/filings/0001628280-24-023185.md) | [4.6](/filings/0001628280-24-037186.md) | [3.9](/filings/0001628280-24-047890.md) | [3.2](/filings/0001040896-26-000009.md) | [7.0](/filings/0001628280-25-025086.md) | [5.1](/filings/0001040896-25-000017.md) | [6.4](/filings/0001040896-25-000032.md) | [3.8](/filings/0001040896-26-000035.md) | [5.6](/filings/0001040896-26-000020.md) | [3.1](/filings/0001040896-26-000035.md) |
| Shareholders' equity | $m | [16.0](/filings/0001628280-24-047890.md) | [17.3](/filings/0001040896-26-000009.md) | [17.2](/filings/0001040896-25-000017.md) | [17.3](/filings/0001040896-25-000032.md) | [16.7](/filings/0001040896-25-000032.md) | [17.7](/filings/0001040896-26-000035.md) | [17.6](/filings/0001040896-26-000035.md) | [18.0](/filings/0001040896-26-000035.md) | [18.9](/filings/0001040896-25-000032.md) | [20.7](/filings/0001040896-26-000035.md) | [21.5](/filings/0001040896-26-000035.md) | [22.5](/filings/0001040896-26-000035.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(258) d](/filings/0001628280-24-047890.md) | [467 d](/filings/0001628280-25-015555.md) | [869](/filings/0001628280-25-025086.md) | [(1,181) d](/filings/0001040896-25-000017.md) | [(1,061) d](/filings/0001040896-25-000032.md) | [(1,321) d](/filings/0001040896-26-000009.md) | [750](/filings/0001040896-26-000020.md) | [3,134 d](/filings/0001040896-26-000035.md) | [(1,737) d](/filings/0001040896-25-000032.md) | [2,394 d](/filings/0001040896-26-000009.md) | [445](/filings/0001040896-26-000020.md) | [1,797 d](/filings/0001040896-26-000035.md) |
| Capital expenditure | $k | [37.0 d](/filings/0001628280-24-047890.md) | [25.0 d](/filings/0001628280-25-015555.md) | [9.0](/filings/0001628280-25-025086.md) | [10.0 d](/filings/0001040896-25-000017.md) | [28.0 d](/filings/0001040896-25-000032.md) | [10.0 d](/filings/0001040896-26-000009.md) | [9.0](/filings/0001040896-26-000020.md) | [13.0 d](/filings/0001040896-26-000035.md) | [22.0 d](/filings/0001040896-25-000032.md) | [8.0 d](/filings/0001040896-26-000009.md) | [33.0](/filings/0001040896-26-000020.md) | [26.0 d](/filings/0001040896-26-000035.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [18.9](/filings/0001628280-23-038914.md) | [19.1](/filings/0001628280-24-023185.md) | [19.1](/filings/0001628280-24-037186.md) | [19.3](/filings/0001628280-24-047890.md) | [19.4](/filings/0001628280-25-025086.md) | [19.5](/filings/0001040896-25-000017.md) | [19.5](/filings/0001040896-25-000032.md) | [19.8](/filings/0001040896-26-000020.md) | [19.8](/filings/0001040896-26-000035.md) | [20.8](/filings/0001040896-25-000032.md) | [20.9](/filings/0001040896-26-000020.md) | [20.9](/filings/0001040896-26-000035.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 20,266,743 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001040896-26-000035.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.